Oncology
Jemperli · rectal cancer
Accelerated approval · As of
AZUR-1 enrolled patients with previously untreated stage II or III locally advanced rectal cancer with MSI-high or mismatch-repair-deficient tumors.
Milestone history
ClinicalTrials.gov first posted the AZUR-1 study record (NCT05723562).
ClinicalTrials.govAZUR-1 began enrolling patients, according to the study record.
ClinicalTrials.govFDA granted accelerated approval for the biomarker-defined rectal cancer indication.
FDA